Connor, Clark & Lunn Investment Management (CC&L)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,409	Closed	-$326K	–	1567
2024 Q2	$326K	Sell	7,409 -17,717	-71%	-$750K	﹤0.01%	1164
2024 Q1	$1.26M	Buy	25,126 +7,890	+46%	+$428K	0.01%	812
2023 Q4	$1.04M	Buy	+17,236	New	+$888K	﹤0.01%	852
2023 Q3	–	Sell	-9,421	Closed	-$480K	–	1468
2023 Q2	$480K	Buy	+9,421	New	+$253K	﹤0.01%	991

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MLTX Position: Q3 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2024, closing a stake of 7,409 shares — an estimated $326K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MLTX in Q2 2023 and held it in 4 quarters. The position peaked at $1.26M in Q1 2024. 109 funds tracked by Wall St. Rank hold MLTX as of Q3 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining MoonLake Immunotherapeutics position as of Q3 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 7,409 MoonLake Immunotherapeutics shares in Q3 2024, an estimated $326K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 4 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s MoonLake Immunotherapeutics position peaked at $1.26M in Q1 2024.
109 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2024, filed 8 Nov 2024.